Protection against soman-induced seizures in rats: Relationship among doses of prophylactics, soman, and adjuncts

Toxicology and Applied Pharmacology

Volumn 196, Issue 3, 2004, Pages 327-336

  Myhrer, Trond ^a   Nguyen, Nga H T ^a   Andersen, Jannike M ^a   Aas, Pål ^a  

^a NORWEGIAN DEFENCE RESEARCH ESTABLISHMENT FFI   (Norway)

Author keywords

Diazepam; Pentobarbital; Physostigmine; Posttreatment; Pretreatment; Procyclidine; Scopolamine; Seizures; Soman poisoning

Indexed keywords

DIAZEPAM; DIZOCILPINE; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PENTOBARBITAL; PHENCYCLIDINE; PHYSOSTIGMINE; PROCYCLIDINE; SCOPOLAMINE; SOMAN; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; COGNITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CONVULSION; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; LD 50; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROPHYLAXIS; RAT; RELIABILITY; SEIZURE;

ANIMALS; CHOLINESTERASE INHIBITORS; CONVULSANTS; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; HIPPOCAMPUS; MALE; MUSCARINIC ANTAGONISTS; NEUROPROTECTIVE AGENTS; PHYSOSTIGMINE; PROCYCLIDINE; RATS; RATS, WISTAR; SCOPOLAMINE; SEIZURES; SOMAN;

EID: 1942535824     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2004.01.007     Document Type: Article

References (37)

1. 14C pyridostigmine in the rat. Br. J. Pharmacol. 26:1966;393-402.
2. Bland B.H. The physiology and pharmacology of hippocampal formation theta rhythms. Prog. Neurobiol. 26:1986;1-54.
3. Bland B.H., Oddie S.D. Theta band oscillation and synchrony in the hippocampal formation and associated structures: the case of its role in sensorimotor integration. Behav. Brain Res. 127:2001;119-136.
4. Bland B.H., Whishaw I.Q. Generators and topography of hippocampal theta (RSA) in the anaesthetized and freely moving rat. Brain Res. 118:1976;259-280.
5. Braitman D.J., Sparenborg S. MK-801 protects against seizures induced by the cholinesterase inhibitor soman. Brain Res. Bull. 23:1989;145-148.
6. Capacio B.R., Shih T.-M. Anticonvulsant actions of anticholinergic drugs in soman poisoning. Epilepsia. 32:1991;604-615.
7. Carpentier P., Lambrinidis M., Blanchet G. Early dendritic changes in hippocampal pyramidal neurones (field CA1) of rats subjected to acute soman intoxication: a light microscopic study. Brain Res. 541:1991;293-299.
8. Gao Z.G., Liu B.Y., Cui W.Y., Li L.J., Fan Q.H., Liu C.G. Anti-nicotonic properties of anticholinergic antiparkinson drugs. J. Pharm. Pharmacol. 50:1998;1299-1305.
9. Harris L.W., McDonough J.H. Jr., Stitcher D.L., Lennox W.J. Protection against both lethal and behavioural effects of soman. Drug Chem. Toxicol. 7:1984;605-624.
10. Kim Y.-B., Hur G.-H., Lee Y.-S., Han B.-G., Shin S.-H. A role of nitric oxide in organophosphate-induced convulsions. Environ. Toxicol. Pharmacol. 3:1997;53-56.
11. Kim Y.-B., Cheon K.-C., Hur G.-M., Phi T.-S., Choi S.-J., Hong D., Kang J.-K. Effects of combinational prophylactics composed of physostigmine and procyclidine on soman-induced lethality, seizures and brain injuries. Environ. Toxicol. Pharmacol. 11:2002;15-21.
12. Lallement G., Denoyer M., Collet A., Pernot-Mariono I., Baubichon D., Monmaur P., Blanchet G. Changes in hippocampal acetylcholine and glutamate extracellular levels during soman-induced seizures: influence of septal cholinoceptive cells. Neurosci. Lett. 139:1992;104-107.
13. Lallement G., Dorandeu F., Filliat P., Carpentier P., Baille V., Blanchet G. Medical management of organophosphate-induced seizures. J. Physiol. (Paris). 92:1998;369-373.
14. Lennox W.J., Harris L.W., Talbot B.G., Anderson D.R. Relationship between reversible acetylcholinesterase inhibition and efficacy against soman lethality. Life Sci. 37:1985;793-798.
15. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
16. Marvizon J.C.G., Skolnick P. An endogenous modulator of N-methyl-D-aspartate receptor-coupled glycine receptors. Eur. J. Pharmacol. 188:1990;23-32.
17. McDonough J.H. Jr., Shih T.-M. Pharmacological modulation of soman-induced seizures. Neurosci. Biobehav. Rev. 17:1993;203-215.
18. McDonough J.H. Jr., Shih T.-M. A study of the N-methyl-D-aspartate antagonistic properties of anticholinergic drugs. Pharmacol. Biochem. Behav. 51:1995;249-253.
19. McDonough J.H. Jr., Shih T.-M. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci. Biobehav. Rev. 21:1997;559-579.
20. McDonough J.H. Jr., Jaax N.K., Crowley R.A., Mays M.Z., Modrow H.E. Atropine and/or diazepam therapy protects against soman-induced neural and cardiac pathology. Fundam. Appl. Toxicol. 13:1989;256-276.
21. McDonough J.H. Jr., Dochterman W., Smith C.D., Shih T.-M. Protection against nerve agent-induced neuropathology, but not cardiac pathology, is associated with the anticonvulsant action of drug treatment. Neurotoxicology. 15:1995;123-132.
22. Myhrer T. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res. Rev. 41:2003;268-287.
23. Myhrer T., Skymoen L.R., Aas P. Pharmacological agents, hippocampal EEG, and anticonvulsant effects on soman-induced seizures in rats. Neurotoxicology. 24:2003;357-367.
24. Myhrer T., Enger S., Aas P. Cognitive side effects in rats caused by pharmacological agents used to prevent soman-induced lethality. Eur. J. Pharmacol. 483:2004;271-279.
25. Olney J.W., Price M.T., Labruyere J., Salles K.S., Frierdich G., Mueller M., Silverman E. Anti-Parkinson agents are phencyclidine agonists and N-methyl-aspartate antagonists. Eur. J. Pharmacol. 142:1987;319-320.
26. Pellegrino L.J., Cushman A.J. A Stereotaxic Atlas of the Rat Brain. 1967;Appleton-Century-Crofts, New York.
27. Raveh L., Weissman B.A., Cohen G., Alkalay D., Rabinovitz I., Sonego H., Brandeis R. Caramiphen and scopolamine prevent soman-induced brain damage and cognitive dysfunction. Neurotoxicology. 23:2002;7-17.
28. Schmued L.C., Hopkins K.J. Fluoro-Jade: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 874:2000;123-130.
29. Schmued L.C., Albertson C., Slikker W. Jr. Fluoro-Jade B: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 751:1997;37-46.
30. Shih T.-M., McDonough J.H. Efficacy of biperiden and atropine as anticonvulsant treatment for organophosphorus nerve agent intoxication. Arch. Toxicol. 74:2000;165-172.
31. Shih T.-M., McDonough J.H. Jr., Koplovitz I. Anticonvulsants for soman-induced seizure activity. J. Biomed. Sci. 6:1999;86-96.
32. Singer A.W., Jaax N.K., Graham J.S., McLeod C.G. Jr. Cardiomyopathy in soman and sarin intoxicated rats. Toxicol. Lett. 36:1987;243-249.
33. Sterri S.H., Lyngaas S., Fonnum F. Toxicity of soman after repetitive injection of sublethal doses in rat. Acta Pharmacol. Toxicol. 46:1980;1-7.
34. Taylor P. Anticholinesterase agents. Gilman A.G., Gooman L.S., Rall T.W., Murad F. The Pharmacological Basis of Therapeutics. 6th ed. 1985;110-129 Mcmillan, New York.
35. Waelbroeck M., Camus J., Tastenoy M., Lambrecht G., Mutschler E.T.R., Christophe J. Stereoselectivity of procyclidine binding to muscarinic receptor subtypes M1, M2 and M4. Eur. J. Pharmacol. 189:1990;135-142.
36. Wetherell J.R. Continuous administration of low dose rates of physostigmine and hyoscine to guinea-pigs prevents the toxicity and reduces the incapacitation produced by soman poisoning. J. Pharm. Pharmacol. 46:1994;1023-1038.
37. Whiteman P.D., Fowle A.S.E., Hamilton M.J., Peck A.W., Bye A., Dean K., Webster A. Pharmacokinetics and pharmacodynamics of procyclidine in man. Eur. J. Clin. Pharmacol. 28:1989;73-78.